• Journal of Korean Society of Forest Science
• /
• v.99 no.1
• /
• pp.9-15
• /
• 2010

This study was conducted to develop a stand growth model and a stand yield table for Eucalyptus pellita and Acacia mangium plantations in Kalimantan, Indonesia. To develop a stand growth model, Weibull robability density function, a diameter class model, was applied in this study. In the development of stand growth model by site index and stand age, a hierarchy is generally required - estimation, recovery and prediction of the diameter class model. A number of grow equations were also involved in each process to estimate diameter, height, basal area, minimum or maximum diameter. To examine whether the grow equations are adequate for Eucalyptus pellita or Acacia mangium plantations, a fitness index was analyzed for each equation. The results showed that fitness indices were ranged from 65 to 89% for Eucalyptus pellita plantations and from 72 to 95% for Acacia mangium plantations. As being highly adequate for the plantations, a stand yield table was developed based on the resulted growth model, and applied to estimate the stand growth with midium site index for 10-year period. The highest annual stand growth of Eucalyptus pellita plantations was estimated to be 21.25 $m^3$/ha, while that of Acacia mangium plantations was 27.5 $m^3$/ha. In terms of annual stand growth, Acacia mangium plantations appeared to be more beneficial than Eucalyptus pellita plantations. Also, to estimate commercial timber volume available from the plantations, an assumption that a log would be cut by 2.7 m in length and the rest of the log would be cut by 1.5m was involved. The commercial timber volume available from Eucalyptus pellita plantations was 68.0 $m^3$/ha, 33% from the total stand volume, 203.2 $m^3$/ha. Also 96.7 $m^3$/ha of commercial timbers were available from Acacia mangium plantations, which was 42% from the 232.9 $m^3$/ha in total. Presenting a good information about the stand growth in Eucalyptus pellita and Acacia mangium plantations, this study might be useful for whom proceeds or considers an abroad plantation for merchantable timber production or carbon credit in tropical regions.

• Tuberculosis and Respiratory Diseases
• /
• v.66 no.6
• /
• pp.444-450
• /
• 2009

Background: Biomarkers for cancer have several potential clinical uses, including the following: early cancer detection, monitoring for recurrence prognostication, and risk stratification. However, no biomarker has been shown to have adequate sensitivity and specificity. Many investigators have tried to validate biomarkers for the early detection and recurrence of lung cancer. To evaluate plasma G-CSF as such a biomarker, protein levels were measured and were found to correlate with the clinicopathological features of primary lung tumors. Methods: Between December 2006 and May 2008, 100 patients with histologically-validated primary lung cancer were enrolled into this study. To serve as controls, 127 healthy volunteers were enrolled into this study. Plasma G-CSF levels were measured in lung cancer patients using the sandwich ELISA system (R & D inc.) prior to treatment. Results: The mean plasma G-CSF levels were 12.2$\pm$0.3 pg/mL and 46.0$\pm$3.8 pg/mL (mean$\pm$SE) in the normal and in the cancer groups, respectively. In addition, plasma G-CSF levels were higher in patients with early lung cancer than in healthy volunteers (p<.001). Plasma G-CSF levels were higher in patients who were under 65 years old or smokers. Within the cancer group, plasma G-CSF levels were higher in patients with non small cell lung cancer than in patients with small cell lung cancer (p<.05). Overall, plasma G-CSF levels were shown to increase dependent upon the type of lung cancer diagnsosed. In the order from highest to lowest, the levels of plasma G-CSF tended to decrease in the following order: large cell carcinoma, squamous cell carcinoma, adenocarcinoma, and bronchioloalveolar carcinoma. Plasma G-CSF levels tended to be higher in patients with advanced TNM stage than in localized TNM stage (I, II

• Radiation Oncology Journal
• /
• v.26 no.1
• /
• pp.65-73
• /
• 2008

Purpose: Women with breast cancer diagnosed at an age of 40 years or younger have a greater prevalence of germline BRCA1 and BRCA2 mutations than the prevalence of women with breast cancer diagnosed at older ages. Several immunohistochemical characteristics have been identified in breast cancers from studies of Caucasian women with BRCA1/2 mutations having familial or early-onset breast cancers. The aim of this study is to determine whether early-onset breast cancer in BRCA1 or BRCA2 mutation carriers, who were not selected from a family history, could be distinguished by the use of immunohistochemical methods and could be distinguished from breast cancer in women of a similar age without a germline BRCA1 or BRCA2 mutation. We also analyzed the prognostic difference between BRCA1/2 related and BRCA1/2 non-related patients by the use of univariate and multivariate analysis. Materials and Methods: Breast cancer tissue specimens from Korean women with early-onset breast cancers were studied using a tumor tissue microarray. Immunohistochemical staining of estrogen receptor(ER), progesterone receptor(PR) and HER-2, as well as the histology and grade of these specimens, were compared. The prognostic impact of immunohistochemical and histological factors as well as the BRCA1/2 mutation status was investigated separately. Results: There were 14 cases and 16 deleterious BRCA1/2 mutations among 101 patients tested. A family history(4/14) and bilateral breast cancers(3/9) were high risk factors for BRCA1/2 mutations. BRCA1/2-associated cancers demonstrated more expression of ER-negative(19.4% versus 5.1%, p=0.038) and HER-2 negative than BRCA1/2 negative tumors, especially for tumors with BRCA1 tumors The BRCA1/2 mutation rate for patients with triple negative tumors(negative expression of ER, PR and HER-2) was 24.2%. Tumor size, nodal status, and HER-2 expression status were significantly associated with disease free survival, as determined by univariate and multivariate analysis, but the BRCA1/2 status was not a prognostic factor. Conclusion: Breast cancer that occurs in women with a germline BRCA1 or BRCA2 mutations have recognizable immunohistochemical features, which may be useful in identifying individuals that are more likely to carry germline mutations. Although the BRCA1/2 mutation status was not a prognostic factor in Korean women with early-onset breast cancer, more cases with a longer follow-up period are needed for further study.